NewsMarkets

Business

Hims & Hers Partners With Eli Lilly to Sell Zepbound and Foundayo Directly

The telehealth company will sell the weight-loss drugs directly to patients paying out of pocket, ending its compounding of GLP-1 medications.

2 publishers · 6 articles · first seen 6 Nov 2026 · updated 9d ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

This story has stopped developing; this page is its permanent record. More from that day

The story so far

2 publishers have covered this in 6 articles since 6 Nov 2026. Quartz published first, on 6 November at 13:50 UTC; MarketWatch followed 2h 39m later. The most recent article, from Quartz, appeared on 6 November at 18:30 UTC.

Outlets reporting it: Quartz, MarketWatch.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Eli Lilly und Hims & Hers haben eine Vereinbarung über den direkten Verkauf von Adipositas-Medikamenten getroffen. Quartz
  2. Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying. MarketWatch
  3. Eli Lilly und Hims & Hers haben einen Vertrag über den direkten Verkauf von Adipositas-Medikamenten abgeschlossen. Quartz
  4. Eli Lilly arbeitet mit Hims & Hers zusammen, um seine Medikamente zur Gewichtsabnahme zu verkaufen. Quartz
  5. Eli Lilly is partnering with Hims & Hers to sell its weight loss drugs Quartz
  6. Eli Lilly arbeitet mit Hims & Hers zusammen, um seine Gewichtsverlusstabletten zu verkaufen. Quartz

In this story

  • Hims & Hers
  • Eli Lilly
Embed this story

Paste this into any web page to show the live odds, with a link back here.